Piramal Pharma Secures SBTi Validation for 42% GHG Reduction by 2030

• Piramal Pharma commits to reducing GHG emissions by 42% by 2030.

• SBTi validates Piramal Pharma’s near-term climate targets.

Piramal Pharma has received official validation from the Science Based Targets Initiative (SBTi) for its near-term greenhouse gas (GHG) emission reduction targets. The company’s commitment includes reducing scope 1 and 2 emissions by 42% by FY2030, using FY2022 as the base year.

In addition to this, Piramal Pharma has committed to cutting its scope 3 emissions, related to upstream activities like purchased goods, energy use, and product transportation, by 25% within the same period. These reductions are part of the company’s sustainability roadmap aimed at supporting global climate action.

Nandini Piramal, Chairperson of Piramal Pharma Limited, stated, “Sustainability is at the heart of our business strategy, and the approval from SBTi reinforces our ongoing commitment to reducing our GHG emissions and aligning with global climate action goals.” She also mentioned that the company is working on a comprehensive Carbon Reduction Plan to be unveiled soon.

The validation by SBTi aligns with Piramal Pharma’s broader purpose of “Doing Well and Doing Good,” reinforcing its commitment to making measurable progress toward environmental sustainability.